<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Secukinumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Secukinumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Secukinumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="99569" href="/d/html/99569.html" rel="external">see "Secukinumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="101418" href="/d/html/101418.html" rel="external">see "Secukinumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27121746"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cosentyx;</li>
<li>Cosentyx (300 MG Dose);</li>
<li>Cosentyx Sensoready (300 MG);</li>
<li>Cosentyx Sensoready Pen;</li>
<li>Cosentyx UnoReady</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871881"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cosentyx</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56044765"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-interleukin 17A Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Antipsoriatic Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F56044810"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b08108e-7d57-4eb2-b521-5882a0b06767">Enthesitis-related arthritis, active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enthesitis-related arthritis, active: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;50 kg: SUBQ: 75 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 75 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: SUBQ: 150 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46fc9b4b-22ea-4096-b090-0ebc9997e04a">Plaque psoriasis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;50 kg: SUBQ: 75 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 75 mg every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: SUBQ: 150 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); some may require higher dose of 300 mg every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cosentyx.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cosentyx.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: SUBQ: 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. Some patients may only require 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;50 kg: SUBQ: 75 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 75 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: SUBQ: 150 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: SUBQ: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active psoriatic arthritis.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: SUBQ: 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active ankylosing spondylitis.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56044821"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F56044822"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F27063835"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="99569" href="/d/html/99569.html" rel="external">see "Secukinumab: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Prior to initiation, certain assessments (clinical and laboratory) are <b>required</b> with documentation and ensure age-appropriate vaccinations <b>are</b> up to date. In general, live vaccines should not be administered within 4 weeks prior to starting therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30772098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30772098'])">Ref</a></span>). Refer to institutional protocols for vaccination and monitoring requirements prior to initiating therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: 6 mg/kg at week 0 followed by 1.75 mg/kg (do not exceed 300 mg) every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: 1.75 mg/kg (do not exceed 300 mg) every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active ankylosing spondylitis.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active ankylosing spondylitis.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="817fad1b-2b47-4cdb-aa3f-b5198ee7cd94">Axial spondyloarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Axial spondyloarthritis (nonradiographic):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: 6 mg/kg at week 0 followed by 1.75 mg/kg (do not exceed 300 mg) every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: 1.75 mg/kg (do not exceed 300 mg) every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: 150 mg every 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a5c771-d06c-4f42-a40c-2a0c6db81cba">Hidradenitis suppurativa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa: SUBQ:</b> 300 mg at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks; consider an increase to 300 mg every 2 weeks in patients who have an inadequate response<b>.</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4fb8c5f3-a1b3-4ba3-b517-cc8663ef3c7c">Plaque psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plaque psoriasis:</b>
<b>SUBQ</b>
<b>:</b> 300 mg once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Some patients may only require 150 mg per dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: 6 mg/kg at week 0 followed by 1.75 mg/kg (do not exceed 300 mg) every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: 1.75 mg/kg (do not exceed 300 mg) every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">With a loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active psoriatic arthritis.</p>
<p style="text-indent:-2em;margin-left:6em;">Without a loading dose: 150 mg every 4 weeks; consider an increase to 300 mg every 4 weeks in patients who continue to have active psoriatic arthritis.</p>
<p style="text-indent:-2em;margin-left:4em;">Coexistent moderate to severe plaque psoriasis: 300 mg once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Some patients may only require 150 mg per dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991715"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989050"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F58899703"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various cutaneous reactions have been reported, including <b>psoriasiform eruption</b> (either new onset or exacerbation), <b>eczematous rash</b>, <b>lupus-like syndrome</b>, <b>bullous pemphigoid</b>, <b>alopecia</b>, <b>skin granuloma</b>, <b>pyoderma gangrenosum</b>, hidradenitis suppurativa, and <b>hypersensitivity angiitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36369405','lexi-content-ref-37449310','lexi-content-ref-34258759','lexi-content-ref-32045273','lexi-content-ref-32115666','lexi-content-ref-32941717','lexi-content-ref-33511635','lexi-content-ref-28954128','lexi-content-ref-35694729','lexi-content-ref-34309516','lexi-content-ref-35614844','lexi-content-ref-35393910','lexi-content-ref-Nyckowski.2017','lexi-content-ref-36151938','lexi-content-ref-36880309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36369405','lexi-content-ref-37449310','lexi-content-ref-34258759','lexi-content-ref-32045273','lexi-content-ref-32115666','lexi-content-ref-32941717','lexi-content-ref-33511635','lexi-content-ref-28954128','lexi-content-ref-35694729','lexi-content-ref-34309516','lexi-content-ref-35614844','lexi-content-ref-35393910','lexi-content-ref-Nyckowski.2017','lexi-content-ref-36151938','lexi-content-ref-36880309'])">Ref</a></span>). In one systematic review, eczematous rash incidence was reported in 2.6% to 7.6% of patients and led to discontinuation in 76% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35614844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35614844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; psoriasiform reactions, eczematous rashes: Possibly related to imbalances of Th1/Th2 immune response. Hypersensitivity angiitis: Possibly related to cytokine imbalance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35614844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35614844'])">Ref</a></span>). Skin granulomas due to <b>sarcoidosis</b>: Proposed imbalance between interleukin-17 and IFN-γ producing T cells that induce IFN-γ secretion, resulting in granuloma formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nyckowski.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nyckowski.2017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Alopecia: Delayed; 2 to 13 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36151938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36151938'])">Ref</a></span>). Eczematous rashes: Delayed; mean 20 weeks (range: 2 to 76 weeks) after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35614844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35614844'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Secukinumab may increase the risk of <b>infection</b>, including <b>serious infection</b> (and sometimes fatal). A higher rate of infections was observed with secukinumab treatment in clinical trials, including <b>nasopharyngitis</b>, <b>upper respiratory tract infection</b>, and <b>candidiasis</b>. Other infections include, but are not limited to, <b>herpes virus infection</b> and <b>staphylococcal infection</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; cytokine inhibition leads to diminished inflammatory response, especially adaptive immunity, against pathogens. Interleukin (IL)-17 is involved in host immunity against extracellular bacteria and fungi (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36355537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36355537'])">Ref</a></span>). Defects in IL-17 immunity are associated with serious infections, including <i>Staphylococcus aureus</i> and herpesvirus skin infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35088874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35088874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of chronic or recurrent infection</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Inflammatory bowel disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment with secukinumab may cause exacerbations or new onset of <b>inflammatory bowel</b>
<b>disease</b> (IBD). <b>Crohn disease</b>, <b>exacerbation of Crohn disease</b>, <b>ulcerative colitis</b>, <b>exacerbation of ulcerative colitis</b>, undifferentiated cases of IBD, and <b>colitis </b>(including microscopic and undifferentiated cases) have been reported with interleukin (IL)-17 inhibitor use, including secukinumab; fatal cases have occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33411953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33411953'])">Ref</a></span>). Overall incidence of IBD with secukinumab is low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34696593','lexi-content-ref-30674475','lexi-content-ref-35754494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34696593','lexi-content-ref-30674475','lexi-content-ref-35754494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> IL-17 may play a protective role in gastrointestinal inflammation, inhibiting a Th1 immune-mediated response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34696593','lexi-content-ref-33411953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34696593','lexi-content-ref-33411953'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; usually within 6 months but may occur as late as 39 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34696593','lexi-content-ref-33411953','lexi-content-ref-32289401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34696593','lexi-content-ref-33411953','lexi-content-ref-32289401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Psoriasis, psoriatic arthritis, or ankylosing spondylitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33411953','lexi-content-ref-30674475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33411953','lexi-content-ref-30674475'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33411953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33411953'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32289401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32289401'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tuberculosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Adult and pediatric patients treated with secukinumab may be at risk for tuberculosis (TB) disease (including reactivated TB). However, an overall low rate of TB has been reported with secukinumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33001147','lexi-content-ref-28868144','lexi-content-ref-35385362','lexi-content-ref-31881026','lexi-content-ref-35616884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33001147','lexi-content-ref-28868144','lexi-content-ref-35385362','lexi-content-ref-31881026','lexi-content-ref-35616884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Interleukin (IL)-17 may promote intracellular growth of <i>Mycobacterium tuberculosis</i> by inhibiting apoptosis of infected macrophages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26483789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26483789'])">Ref</a></span>). Hence, IL-17 inhibition appears to be favorable regarding TB infection; may limit intracellular growth of <i>Mycobacterium tuberculosis</i> by enhancing apoptosis of infected macrophages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31881026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31881026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Residence in an area with high TB prevalence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35616884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35616884'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F27164803"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (29% to 48%; serious infection: ≤1%)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Secukinumab: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Secukinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Secukinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,430</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,382</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">694</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,430</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious: 0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious: 0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,382</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">694</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (11% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Nasopharyngitis table link" class="lexi-table-link" data-table-id="lexi-content-nasopharyngitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nasopharyngitis')">table 2</a>)</span><span class="table-link" style="display:none;">Nasopharyngitis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nasopharyngitis" frame="border" id="lexi-content-nasopharyngitis" rules="all">
<caption style="text-align:center;">
<b>Secukinumab: Adverse Reaction: Nasopharyngitis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Secukinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Secukinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">692</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">694</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">691</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">694</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3% to 4%), inflammatory bowel disease (≤1%; Crohn disease, exacerbation of Crohn disease, exacerbation of ulcerative colitis, ulcerative colitis: &lt;1%), mucocutaneous candidiasis (1%), nausea (≥2%), oral herpes simplex infection (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (1%), rhinitis (1%), rhinorrhea (≤1%), upper respiratory tract infection (3%)<span class="lexi-table-link-container"> (<a aria-label="Upper Respiratory Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-upper-respiratory-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-upper-respiratory-tract-infection')">table 3</a>)</span><span class="table-link" style="display:none;">Upper Respiratory Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Upper Respiratory Tract Infection" frame="border" id="lexi-content-upper-respiratory-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Secukinumab: Adverse Reaction: Upper Respiratory Tract Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Secukinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Secukinumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">691</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">694</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">692</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">694</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Impetigo, tinea pedis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (including neutralizing; effect of neutralizing antibodies on safety, efficacy, or PK/PD is unknown)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis externa, otitis media</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis, tonsillitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis, gastritis, hematochezia, lower abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Öğüt 2023), bullous pemphigoid (Wang 2023), eczematous rash (Caldarola 2020), psoriasiform eruption (Karamanakos 2021), pyoderma gangrenosum (Avci 2023), skin granuloma (Fox 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis (Ak 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis (Nyckowski 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (Davidson 2022), herpes virus infection (Davidson 2022), staphylococcal infection (Davidson 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (Grace 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (Liang 2022)</p></div>
<div class="block coi drugH1Div" id="F26938418"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity reaction to secukinumab or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F27063768"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Eczematous eruptions: Severe eczematous eruptions (sometimes requiring hospitalization), including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma have been reported; the onset ranged from days to months after the first dose. Consider discontinuation of therapy until eczematous eruptions resolve.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Urticaria and anaphylaxis have been reported; discontinue immediately if signs/symptoms of a serious hypersensitivity reaction develop and initiate appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Secukinumab may increase the risk of infections. Serious and sometimes fatal infections have been reported. A higher rate of infections was observed with secukinumab treatment in clinical trials, including nasopharyngitis, upper respiratory tract infection, and mucocutaneous candida infection; the incidence of some types of infection appeared to be dose-dependent. Use with caution in patients with a chronic infection or a history of recurrent infection. In patients who develop a serious infection, monitor closely and discontinue use until the infection resolves.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: Patients should be evaluated for tuberculosis (TB) infection (latent TB) prior to initiating therapy; avoid therapy in patients with TB disease (active TB). Consider antituberculosis therapy if an adequate course of treatment cannot be confirmed in patients with a history of TB disease or infection. Monitor all patients for signs and symptoms of TB disease during and after treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammatory bowel disease: Treatment with secukinumab may cause exacerbations (some serious) and new onset of inflammatory bowel of inflammatory bowel disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold biologic disease-modifying antirheumatic drugs (DMARDs) prior to surgery and plan surgery after the next dose is due. Surgery can occur after holding medication for 1 full dosing cycle (eg, for medications administered every 4 weeks, schedule surgery 5 weeks from last administered dose); therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk). Decisions to withhold therapy should be based on shared decision making; ensure the patient and their provider weigh risks of interrupting therapy and disease control versus risks of continuing therapy and surgical complications (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some dosage forms may contain dry natural rubber (latex).</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently during therapy; non-live vaccines administered during secukinumab therapy may not elicit an immune response sufficient to prevent disease.</p></div>
<div class="block foc drugH1Div" id="F27121747"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx: 125 mg/5 mL (5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx Sensoready (300 MG): 150 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx Sensoready Pen: 150 mg/mL (1 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx UnoReady: 300 mg/2 mL (2 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx: 75 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx: 150 mg/mL (1 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx (300 MG Dose): 150 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F27121745"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F27265722"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cosentyx Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $507.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Cosentyx Sensoready (300 MG) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $4,445.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Cosentyx Sensoready Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $8,890.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Cosentyx UnoReady Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/2 mL (per mL): $4,445.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Cosentyx (300 MG Dose) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $4,445.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Cosentyx Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg/0.5 mL (per 0.5 mL): $4,445.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $8,890.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871882"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx: 150 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cosentyx: 75 mg/0.5 mL (0.5 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F56044836"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SUBQ: Allow to reach room temperature prior to injection. Inject into the thighs, any quadrant of the abdomen (≥2 inches away from the navel), or outer upper arms; administer each injection at a different anatomic location than a previous injection and avoid areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis, or where there are scars or stretch marks. Do not shake injection device. Pediatric doses of the Sensoready pen or prefilled syringe should be administered by an adult caregiver; trained adult patients may self-administer.</p>
<p style="text-indent:-2em;margin-left:2em;">The 300 mg dose should be divided into two 150 mg SUBQ injections.</p></div>
<div class="block adm drugH1Div" id="F27063840"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Dilute prior to use. Infuse over 30 minutes (~3.3 mL/minute for 100 mL bag or 1.7 mL/minute for a 50 mL bag), using an infusion set with an in-line, sterile, nonpyrogenic, low protein-binding 0.2-micron filter. After infusion is complete, flush line with ≥50 mL of NS. Do not infuse in the same line with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ</b>
<b>:</b> Allow to reach room temperature 15 to 30 minutes (Sensoready pen, 75 mg/0.5 mL prefilled syringe, 150 mg/mL prefilled syringe) or 30 to 45 minutes (UnoReady pen) prior to injection. Inject into the front of thighs, lower abdomen (≥2 inches away from the navel) or outer upper arms; administer each injection at a different anatomic location than a previous injection and avoid areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis, or where there are scars or stretch marks. The pens and prefilled syringes may be self-injected by the patient or caregiver following proper training in SUBQ injection technique.</p></div>
<div class="block sts drugH1Div" id="F27063810"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Pens and prefilled syringes: Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light; keep in original carton. Do not freeze or shake. May store intact Sensoready pens, 150 mg/mL prefilled syringes, and 75 mg/0.5 mL prefilled syringes at ≤30°C (≤86°F) for up to 4 days; may return to the refrigerator once if unused. Discard any unused portion or if stored outside refrigerator &gt;4 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Vials: Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light; keep in original carton. Do not freeze or shake. If diluted solution is not used immediately, may store at 20°C to 25°C (68°F to 77°F) for up to 4.5 hours (preparation to end of infusion) or refrigerated for up to 24 hours (preparation to end of infusion). Protect infusion from light when stored under refrigeration.</p></div>
<div class="block meg drugH1Div" id="F26938696"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Cosentyx: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125504s063lbl.pdf%23page%3D34&amp;token=4lCQWt4xvRRRPlduh%2B%2FleTR6%2F2d4BmMp2dMDNryXy%2FwE%2BI0KmPIG23fjWZd1%2FoV7H9%2FcuYMyhyFdBQNp1obmaYpz0ZbsagCd2o7fSWDeY4JFjCvGZDtQFd%2FJfRK0UWoD&amp;TOPIC_ID=132381" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s063lbl.pdf#page=34</a></p></div>
<div class="block usep drugH1Div" id="F56044773"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of active psoriatic arthritis (FDA approved in ages ≥2 years and adults); treatment of active enthesitis-related arthritis (FDA approved in ages ≥4 years and adults); treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy (FDA approved in ages ≥6 years and adults); treatment of active nonradiographic axial spondyloarthritis with objective signs of inflammation and active ankylosing spondylitis (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F27004278"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F27004275"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Anti-Psoriasis Agents may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belimumab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Management: Consider alternatives to the use of belimumab with other biologic therapies. Monitor closely for increased toxicities related to additive immunosuppression (ie, infection, malignancy) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">InFLIXimab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53688081"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The American Academy of Dermatology considers secukinumab for the treatment of psoriasis to be likely compatible for use in male patients planning to father a child (AAD-NPF [Menter 2019]). Males and females with well-controlled psoriasis who are planning a pregnancy and wish to avoid fetal exposure can consider discontinuing secukinumab 19 weeks prior to attempting pregnancy (Rademaker 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Based on limited information, use of secukinumab may be continued through conception in patients with rheumatic and musculoskeletal diseases who are planning to become pregnant and not able to use alternative therapies; use should be discontinued once pregnancy is confirmed. Conception should be planned during a period of quiescent/low disease activity. Recommendations for use of secukinumab to treat rheumatic and musculoskeletal diseases in patients who are planning to father a child are not available due to limited data (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Possible failure of tubal sterilization following placement of an implantable birth control device (Essure) was observed in a female treated with secukinumab (Nardin 2018). <b>Note:</b> Distribution of Essure in the United States was stopped in December 2018.</p></div>
<div class="block pri drugH1Div" id="F27063661"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Secukinumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following exposure to secukinumab during pregnancy is limited (Liu 2020; Nardin 2018; Warren 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Until additional information is available, secukinumab is not currently recommended for the treatment of rheumatic and musculoskeletal diseases during pregnancy. Secukinumab should be discontinued once pregnancy is confirmed (ACR [Sammaritano 2020]). Agents other than secukinumab are preferred for the treatment of plaque psoriasis during pregnancy (Yeung 2020).</p></div>
<div class="block mopp drugH1Div" id="F56044837"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Tuberculosis (TB) screening prior to initiating and during therapy (yearly if high risk); baseline hepatitis virus and HIV screening in patients with relevant risk factors (AAD-NPF [Menter 2020]); signs and symptoms of infection or inflammatory bowel disease.</p></div>
<div class="block pha drugH1Div" id="F27063812"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.</p></div>
<div class="block phk drugH1Div" id="F27063814"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Weight: Secukinumab clearance and volume of distribution increase as body weight increases.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Psoriasis: SUBQ: Response best determined after 12 weeks (AAD-NPF [Menter 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: SUBQ: 7.1 to 8.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways similar to that which is seen with endogenous IgG.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 55% to 77%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SUBQ: 22 to 31 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SUBQ: ~6 days.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27001494"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx | Cosentyx sensoready</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx | Fraizeron</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx | Cosentyx (300 mg Dose) | Cosentyx Sensoready | Cosentyx Sensoready (300 mg Dose)</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cosentyx</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36369405">
<a name="36369405"></a>Ak T, Durmus RB, Onel M. Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature. <i>Clin Rheumatol</i>. 2023;42(2):339-357. doi:10.1007/s10067-022-06406-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/36369405/pubmed" id="36369405" target="_blank">36369405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37449310">
<a name="37449310"></a>Avcı C, Akın G, Akarsu S, Lebe B. Pyoderma gangrenosum and Behçet's-like disease induced by secukinumab: a paradoxical drug reaction. <i>J Dermatolog Treat</i>. 2023;34(1):2235040. doi:10.1080/09546634.2023.2235040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/37449310/pubmed" id="37449310" target="_blank">37449310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34258759">
<a name="34258759"></a>Babino G, D'Ambra I, Fulgione E, Alfano R, Verolino P, Argenziano G. Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab. <i>Int J Dermatol</i>. 2022;61(2):e79-e80. doi:10.1111/ijd.15730<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/34258759/pubmed" id="34258759" target="_blank">34258759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32045273">
<a name="32045273"></a>Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. <i>Expert Opin Biol Ther</i>. 2020;20(6):665-672. doi:10.1080/14712598.2020.1727439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32045273/pubmed" id="32045273" target="_blank">32045273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32115666">
<a name="32115666"></a>Chelli C, Loget J, Vanhaecke C, et al. Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis. <i>Acta Derm Venereol</i>. 2020;100(6):adv00077. doi:10.2340/00015555-3435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32115666/pubmed" id="32115666" target="_blank">32115666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cosentyx.1">
<a name="Cosentyx.1"></a>Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cosentyx.2">
<a name="Cosentyx.2"></a>Cosentyx (secukinumab) [product monograph]. Dublin, Ireland: Novartis Europharm Ltd; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26483789">
<a name="26483789"></a>Cruz A, Ludovico P, Torrado E, et al. IL-17A promotes intracellular growth of mycobacterium by inhibiting apoptosis of infected macrophages. <i>Front Immunol</i>. 2015;6:498. doi:10.3389/fimmu.2015.00498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/26483789/pubmed" id="26483789" target="_blank">26483789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35088874">
<a name="35088874"></a>Davidson L, Van den Reek JMPA, Van Hunsel F, De Jong EMGJ, Kullberg BJ. Global risk of bacterial skin infections and herpesviridae infections with ustekinumab, secukinumab, and tumour necrosis factor-alpha inhibitors: Spontaneous reports of adverse drug reactions from the World Health Organization Pharmacovigilance Center. <i>Acta Derm Venereol</i>. 2022;102:adv00648. doi:10.2340/actadv.v102.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35088874/pubmed" id="35088874" target="_blank">35088874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432853">
<a name="27432853"></a>Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/27432853/pubmed" id="27432853" target="_blank">27432853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33001147">
<a name="33001147"></a>Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab teatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. <i>JAMA Dermatol</i>. 2021;157(1):43-51. doi:10.1001/jamadermatol.2020.3257. Erratum in: <i>JAMA Dermatol</i>. 2021;157(1):124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/33001147/pubmed" id="33001147" target="_blank">33001147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36355537">
<a name="36355537"></a>Eshwar V, Kamath A, Shastry R, Shenoy AK, Kamath P. A review of the safety of interleukin-17A inhibitor secukinumab. <i>Pharmaceuticals (Basel)</i>. 2022;15(11):1365. doi:10.3390/ph15111365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/36355537/pubmed" id="36355537" target="_blank">36355537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32941717">
<a name="32941717"></a>Fox JD, Aramin H, Ghiam N, Freedman JB, Romanelli P. Secukinumab-associated localized granuloma annulare (SAGA): a case report and review of the literature. <i>Dermatol Online J</i>. 2020;26(8):13030/qt1nd6p108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32941717/pubmed" id="32941717" target="_blank">32941717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31734937">
<a name="31734937"></a>Grace E, Goldblum O, Renda L, et al. Injection site reactions in the Federal Adverse Event Reporting System (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. <i>Dermatol Ther (Heidelb)</i>. 2020;10(1):99-106. doi:10.1007/s13555-019-00341-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/31734937/pubmed" id="31734937" target="_blank">31734937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33511635">
<a name="33511635"></a>Gray AR, Davies OMT, White K, Ortega-Loayza AG. Granuloma annulare following initiation of interleukin-17a antagonist. <i>Clin Exp Dermatol</i>. 2021;46(5):924-926. doi:10.1111/ced.14579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/33511635/pubmed" id="33511635" target="_blank">33511635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28954128">
<a name="28954128"></a>Hayashida MZ, Pinheiro JRS, Enokihara MMSES, Vasconcellos MRA. Biologic therapy-induced pemphigus. <i>An Bras Dermatol</i>. 2017;92(4):591-593. doi:10.1590/abd1806-4841.20176481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/28954128/pubmed" id="28954128" target="_blank">28954128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22250239">
<a name="22250239"></a>Hsu S, Papp KA, Lebwohl MG, et al. Consensus Guidelines for the Management of Plaque Psoriasis. <i>Arch Dermatol</i>. 2012;148(1):95-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/22250239/pubmed" id="22250239" target="_blank">22250239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35694729">
<a name="35694729"></a>Husein-ElAhmed H, Steinhoff M. Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. <i>J Dermatolog Treat</i>. 2022;33(7):2886-2893. doi:10.1080/09546634.2022.2089331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35694729/pubmed" id="35694729" target="_blank">35694729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28868144">
<a name="28868144"></a>Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections. <i>Clin Transl Immunology</i>. 2017;6(8):e152. doi:10.1038/cti.2017.34<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/28868144/pubmed" id="28868144" target="_blank">28868144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34309516">
<a name="34309516"></a>Karamanakos A, Vergou T, Panopoulos S, Tektonidou MG, Stratigos AJ, Sfikakis PP. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. <i>Eur J Dermatol</i>. 2021;31(3):307-317. doi:10.1684/ejd.2021.4056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/34309516/pubmed" id="34309516" target="_blank">34309516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35614844">
<a name="35614844"></a>Liang J, Zhang S, Li Q, Yu Y, Chen X, Zhang X. Review of secukinumab-induced adverse events of special interest and its potential pathogenesis. <i>Dermatol Ther</i>. 2022;35(8):e15599. doi:10.1111/dth.15599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35614844/pubmed" id="35614844" target="_blank">35614844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32812054">
<a name="32812054"></a>Liu N, Zhu L, Cheng Y, Yu N, Yi X, Ding Y. Successful treatment of recurrent pustular psoriasis of pregnancy with secukinumab: a case report. <i>Acta Derm Venereol</i>. 2020;100(15):adv00251. doi:10.2340/00015555-3611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32812054/pubmed" id="32812054" target="_blank">32812054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35385362">
<a name="35385362"></a>Megna M, Patruno C, Bongiorno MR, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. <i>J Dermatolog Treat</i>. 2022;33(5):2629-2633. doi:10.1080/09546634.2022.2062280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35385362/pubmed" id="35385362" target="_blank">35385362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32119894">
<a name="32119894"></a>Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>J Am Acad Dermatol</i>. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32119894/pubmed" id="32119894" target="_blank">32119894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30772098">
<a name="30772098"></a>Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.<i> J Am Acad Dermatol</i>. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/30772098/pubmed" id="30772098" target="_blank">30772098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24964946">
<a name="24964946"></a>Mervic L. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2014;23(2):27-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/24964946/pubmed" id="24964946" target="_blank">24964946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35393910">
<a name="35393910"></a>Messina F, Piaserico S. The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. <i>J Dermatolog Treat</i>. 2022;33(5):2443-2454. doi:10.1080/09546634.2022.2062281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35393910/pubmed" id="35393910" target="_blank">35393910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29524191">
<a name="29524191"></a>Nardin C, Colas M, Curie V, Pelletier F, Puzenat E, Aubin F. Pregnancy after tubal sterilization in a woman treated with biologics for severe psoriasis. <i>Dermatol Ther (Heidelb)</i>. 2018;8(2):323-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/29524191/pubmed" id="29524191" target="_blank">29524191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33349983">
<a name="33349983"></a>Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris - part 1: treatment and monitoring recommendations. <i>J Eur Acad Dermatol Venereol</i>. 2020;34(11):2461-2498. doi:10.1111/jdv.16915<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/33349983/pubmed" id="33349983" target="_blank">33349983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nyckowski.2017">
<a name="Nyckowski.2017"></a>Nyckowski T, Ceilley R, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. <i>The National Society for Cutaneous Medicine</i>. 2017;1(2):95-99.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36151938">
<a name="36151938"></a>Öğüt ND. Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab-induced hidradenitis suppurativa and secukinumab-induced alopecia areata. <i>J Eur Acad Dermatol Venereol</i>. 2023;37(4):e468-e469. doi:10.1111/jdv.18601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/36151938/pubmed" id="36151938" target="_blank">36151938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34696593">
<a name="34696593"></a>Ojeda Gómez A, Madero Velázquez L, Buendía Sanchez L, et al. Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center. <i>Rev Esp Enferm Dig</i>. 2021;113(12):858-859. doi:10.17235/reed.2021.8397/2021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/34696593/pubmed" id="34696593" target="_blank">34696593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106107">
<a name="23106107"></a>Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. <i>Brit J Derm</i>. 2013;168:412-421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/23106107/pubmed" id="23106107" target="_blank">23106107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33411953">
<a name="33411953"></a>Petitpain N, D'Amico F, Yelehe-Okouma M, et al. IL-17 inhibitors and inflammatory bowel diseases: A postmarketing study in Vigibase. <i>Clin Pharmacol Ther</i>. 2021;110(1):159-168. doi:10.1002/cpt.2155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/33411953/pubmed" id="33411953" target="_blank">33411953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543445">
<a name="28543445"></a>Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. <i>Australas J Dermatol</i>. 2018;59(2):86-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/28543445/pubmed" id="28543445" target="_blank">28543445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23362969">
<a name="23362969"></a>Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>Brit J Derm</i>. 2013;168:402-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/23362969/pubmed" id="23362969" target="_blank">23362969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30674475">
<a name="30674475"></a>Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Ann Rheum Dis</i>. 2019;78(4):473-479. doi:10.1136/annrheumdis-2018-214273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/30674475/pubmed" id="30674475" target="_blank">30674475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35754494">
<a name="35754494"></a>Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q. Post-marketing safety concerns with secukinumab: A disproportionality analysis of the FDA Adverse Event Reporting System. <i>Front Pharmacol</i>. 2022;13:862508. doi:10.3389/fphar.2022.862508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35754494/pubmed" id="35754494" target="_blank">35754494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36880309">
<a name="36880309"></a>Wang R, Wang A, Wang M. Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: A paradoxical reaction. <i>J Dermatol</i>. 2023;50(7):956-959. doi:10.1111/1346-8138.16765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/36880309/pubmed" id="36880309" target="_blank">36880309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29927479">
<a name="29927479"></a>Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. <i>Br J Dermatol</i>. 2018;179(5):1205-1207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/29927479/pubmed" id="29927479" target="_blank">29927479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32289401">
<a name="32289401"></a>Wright S, Alloo A, Strunk A, Garg A. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors. <i>J Am Acad Dermatol</i>. 2020;83(2):382-387. doi:10.1016/j.jaad.2020.04.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32289401/pubmed" id="32289401" target="_blank">32289401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31881026">
<a name="31881026"></a>Wu CY, Chiu HY, Tsai TF. The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. <i>PLoS One</i>. 2019;14(12):e0225112. doi:10.1371/journal.pone.0225112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/31881026/pubmed" id="31881026" target="_blank">31881026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35616884">
<a name="35616884"></a>Xiao Y, Chen H, Zou Q, et al. The tuberculosis positive conversion rate among psoriasis patients treated with adalimumab and secukinumab: A single-center retrospective study in China. <i>Dermatol Ther (Heidelb)</i>. 2022;12(6):1493-1500. doi:10.1007/s13555-022-00745-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/35616884/pubmed" id="35616884" target="_blank">35616884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32500730">
<a name="32500730"></a>Yeung J, Gooderham MJ, Grewal P, et al. Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper. <i>J Cutan Med Surg</i>. 2020;24(suppl 1):3S-14S. doi:10.1177/1203475420928376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/secukinumab-pediatric-drug-information/abstract-text/32500730/pubmed" id="32500730" target="_blank">32500730</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 132381 Version 78.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
